Detalhe da pesquisa
1.
Improvement of differential diagnosis of lung cancer by use of multiple protein tumor marker combinations.
Tumour Biol
; 46(s1): S81-S98, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38277317
2.
Lack of clinical utility of serum macrophage migration inhibitory factor (MIF) for monitoring therapy response and estimating prognosis in advanced lung cancer.
Tumour Biol
; 46(s1): S341-S353, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-37545291
3.
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.
Lancet
; 389(10066): 255-265, 2017 01 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-27979383
4.
Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First-Line Nonsquamous Non-Small Cell Lung Cancer.
Oncologist
; 23(6): 654-e58, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29438092
5.
Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study.
Lancet Oncol
; 16(3): 328-37, 2015 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-25701171
6.
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial.
Lancet Oncol
; 15(2): 143-55, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24411639
7.
Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial.
Lancet Oncol
; 15(12): 1369-78, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-25439691
8.
Randomized phase II study of three doses of the integrin inhibitor cilengitide versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer.
Invest New Drugs
; 31(1): 175-82, 2013 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-22752690
9.
EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study.
Lancet Oncol
; 13(1): 33-42, 2012 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-22056021
10.
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non-Small-Cell Lung Cancer.
J Clin Oncol
; 41(14): 2458-2466, 2023 May 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37146426
11.
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy.
J Clin Oncol
; 41(15): 2682-2690, 2023 May 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-37196429
12.
A phase II randomized study of cisplatin-pemetrexed plus either enzastaurin or placebo in chemonaive patients with advanced non-small cell lung cancer.
Oncology
; 82(1): 25-9, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-22269428
13.
First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study.
Lancet Oncol
; 12(1): 30-7, 2011 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-21169060
14.
Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study.
Lancet Oncol
; 12(8): 795-805, 2011 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-21782507
15.
Soluble High Mobility Group Box 1 (HMGB1) Is a Promising Biomarker for Prediction of Therapy Response and Prognosis in Advanced Lung Cancer Patients.
Diagnostics (Basel)
; 11(2)2021 Feb 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-33672622
16.
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.
Lancet
; 373(9674): 1525-31, 2009 May 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-19410716
17.
Editorial.
Int J Clin Pharmacol Ther
; 53(12): 1037, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-26564259
18.
Nucleosomes and CYFRA 21-1 indicate tumor response after one cycle of chemotherapy in recurrent non-small cell lung cancer.
Lung Cancer
; 63(1): 128-35, 2009 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-18571761
19.
Nucleosomes, ProGRP, NSE, CYFRA 21-1, and CEA in monitoring first-line chemotherapy of small cell lung cancer.
Clin Cancer Res
; 14(23): 7813-21, 2008 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-19047109
20.
Annual meeting of CESAR in Tuebingen, Germany June 27-29, 2013.
Int J Clin Pharmacol Ther
; 52(1): 73, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-24403101